Home » Stocks » Boston Scientific

Boston Scientific Corporation (BSX)

Stock Price: $39.31 USD 0.33 (0.85%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $39.22 -0.09 (-0.23%) Aug 11, 5:55 PM

Stock Price Chart

Key Info

Market Cap 56.24B
Revenue (ttm) 10.16B
Net Income (ttm) 3.99B
Shares Out 1.43B
EPS (ttm) 2.83
PE Ratio 13.89
Forward PE 36.50
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $39.31
Previous Close $38.98
Change ($) 0.33
Change (%) 0.85%
Day's Open 39.46
Day's Range 39.25 - 39.87
Day's Volume 7,951,489
52-Week Range 24.10 - 46.62

More Stats

Market Cap 56.24B
Enterprise Value 64.05B
Earnings Date (est) Oct 21, 2020
Ex-Dividend Date n/a
Shares Outstanding 1.43B
Float 1.43B
EPS (basic) 2.86
EPS (diluted) 2.83
FCF / Share 0.72
Dividend n/a
Dividend Yield n/a
Earnings Yield 7.20%
FCF Yield 1.81%
Payout Ratio n/a
Shares Short 14.89M
Short Ratio 1.25
Short % of Float 1.04%
Beta 0.95
PE Ratio 13.89
Forward PE 36.50
P/FCF Ratio 55.30
PS Ratio 5.54
PB Ratio 3.47
Revenue 10.16B
Operating Income 669.00M
Net Income 3.99B
Free Cash Flow 1.02B
Net Cash -7.81B
Net Cash / Share -5.46
Gross Margin 75.14%
Operating Margin 6.59%
Profit Margin 39.20%
FCF Margin 10.01%
ROA 2.57%
ROE 31.83%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (26)

Buy 22
Overweight 1
Hold 2
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$45.78*
(16.46% upside)
Low
41.0
Current: $39.31
High
50.0
Target: 45.78
*Average 12-month price target from 23 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue10,7359,8239,0488,3867,4777,3807,1437,2497,6227,806
Revenue Growth9.28%8.57%7.89%12.16%1.31%3.32%-1.46%-4.89%-2.36%-
Gross Profit7,6197,0106,4555,9625,3045,1704,9694,9004,9635,207
Operating Income1,5171,5061,285447-283-31382.00-3,883126-656
Net Income4,7001,671104347-239-119-121-4,068441-1,065
Shares Outstanding1,3921,3811,3701,3581,3411,3241,3411,4071,5091,518
Earnings Per Share3.331.190.080.25-0.18-0.09-0.09-2.890.29-0.70
EPS Growth179.83%1387.5%-68%-------
Operating Cash Flow1,8363101,4261,1826911,2691,1101,2801,008325
Capital Expenditures-402-302-319-347-247-259-192-210-288-267
Free Cash Flow1,4348.001,1078354441,0109181,07072058.00
Cash & Equivalents217146188196319587217207267213
Total Debt10,0087,0565,6165,4845,6774,2444,2404,2564,2615,438
Net Cash / Debt-9,791-6,910-5,428-5,288-5,358-3,657-4,023-4,049-3,994-5,225
Assets30,56520,99919,04218,09618,13317,02416,57117,15421,29022,128
Liabilities16,68812,27312,03011,36311,81310,56710,03210,2849,93710,832
Book Value13,8778,7267,0126,7336,3206,4576,5396,87011,35311,296
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Boston Scientific Corporation
Country United States
Employees 36,000
CEO Michael F. Mahoney

Stock Information

Ticker Symbol BSX
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Appliances & Equipment
Unique Identifier NYSE: BSX
IPO Date May 18, 1992

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.